- In April 2025, CSL announced plans to seek regulatory approval from Chinese authorities to export albumin from its new USD 900 million plasma fractionation facility in Broadmeadows, Melbourne. This move aims to enhance global supply chain resilience and meet the growing demand for plasma-derived therapies in China
- In September 2022, CSL Behring K.K. obtained manufacturing and marketing authorization from Japan's Ministry of Health, Labour and Welfare for Berinert S.C. Injection 2000. This lyophilized human C1-esterase inhibitor concentrate is designed for subcutaneous injection to prevent acute hereditary angioedema (HAE) attacks. The approval marks a significant advancement in plasma-derived therapeutics for HAE patients in Japan
- In September 2022, CSL Behring K.K. received regulatory approval from Japan’s Ministry of Health, Labour and Welfare for Berinert S.C. Injection 2000, a lyophilized human C1-esterase inhibitor designed for subcutaneous administration. This approval represents a key advancement in plasma-derived therapeutics for the prevention of acute hereditary angioedema (HAE) attacks, expanding treatment options in the Japanese market
- In October 2022, Grifols inaugurated a new albumin purification and filling facility in Dublin, Ireland, strengthening its global manufacturing and supply capabilities. This expansion significantly boosts the company’s capacity to produce albumin—an essential plasma-derived product—supporting the growing global demand for plasma fractionation therapies
- In May 2022, Terumo Blood and Cell Technologies opened a new USD 250 million, 170,000-square-foot manufacturing facility in Douglas County, Colorado. The plant is dedicated to producing single-use collection sets for the FDA-approved Rika Plasma Donation System, aiming to bolster plasma collection capabilities and meet the increasing demand for source plasma in the plasma fractionation market
